journal article·2011-07

Zinc-phosphate nanoparticles with reversibly attached TNF-α analogs: an interesting concept for potential use in active immunotherapy

Gorazd Hribar, Andrej Žnidaršič, Marjan Bele, Uroš Maver, Simon Caserman, Miran Gaberšček, Vladka Gaberc-Porekar

Journal of Nanoparticle Research· Volume 13· Issue 7
Publisher page

Abstract

The authors’ intention was to prepare nanometer-sized zinc-phosphate nanoparticles that would be capable of binding histidine-rich TNF-α analogs onto their surface via a coordinative bond. Zinc-phosphate nanoparticles with a size of around 60 nm were prepared by a wet precipitation method and characterized using SEM, EDX, XRD, and DLS. First, BSA was bound as a testing protein, afterward two TNF-α analogs with decreased activity were bound to the described nanoparticles. The efficiency of binding and the existence of coordinative bond were confirmed with SDS-PAGE analysis. During binding, particle storage, and release experiments, the prepared TNF-α analogs retained their biological activity—hence the epitopes necessary for formation of antibodies stayed intact. The particle size did not change within a period of 2 weeks. No significant agglomeration was observed, the particles could be quickly dispersed in ultrasound. The present nanoparticles and the general approach of coordinative binding are widely applicable for natural and engineered histidine-rich proteins. The nanoparticles bearing appropriate TNF-α analogs could also be potentially used for active immunotherapy to tackle the chronic inflammatory diseases associated with pathogenically elevated levels of TNF-α.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Immunotherapy and Immune Responses · Toxin Mechanisms and Immunotoxins · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (28)

Show source-provided references
1. Augustsson J, Jonsdottir T, Klareskog L, van Vollenhoven RF (2006) Infliximab in the treatment of rheumatoid arthritis. Aging Health 2(1):19–3310.2217/1745509X.2.1.19 ↗
2. Bele M, Hribar G, Campelj S et al (2008) Zinc-decorated silica-coated magnetic nanoparticles for protein binding and controlled release. J Chromatogr B 867(1):160–16410.1016/j.jchromb.2008.03.019 ↗
3. Boehncke WH (2007) Etanercept: a soluble TNF-α receptor in the treatment of psoriasis. Therapy 4(5):665–67210.2217/14750708.4.5.665 ↗
4. Chaga GS (2001) Twenty-five years of immobilized metal ion affinity chromatography: past, present and future. J Biochem Biophys Methods 49(1–3):313–33410.1016/S0165-022X(01)00206-8 ↗
5. Chikh GG, Li WM, Schutze-Redelmeier MP, Meunier JC, Bally MB (2002) Attaching histidine-tagged peptides and proteins to lipid-based carriers through use of metal-ion-chelating lipids. Biochim Biophys Acta 1567(1–2):204–21210.1016/S0005-2736(02)00618-1 ↗
6. Dalum I, Butler DM, Jensen MR et al (1999) Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol 17(7):666–66910.1038/10878 ↗
7. Delavallee L, Assier E, Denys A, Falgarone G, Zagury JF, Muller S, Bessis N, Boissier MC (2008) Vaccination with cytokines in autoimmune diseases. Ann Med 40(5):343–35110.1080/07853890801995298 ↗
8. Fonda I, Kenig M, Gaberc-Porekar V, Pristovsek P, Menart V (2002) Attachment of histidine tags to recombinant tumor necrosis factor-alpha drastically changes its properties. Sci World J 2:1312–132510.1100/tsw.2002.215 ↗
9. Frenzel A, Bergemann C, Kohl G, Reinard T (2003) Novel purification system for 6xHis-tagged proteins by magnetic affinity separation. J Chromatogr B 793(2):325–32910.1016/S1570-0232(03)00332-5 ↗
10. Gaberc-Porekar V, Menart V (2001) Perspectives of immobilized-metal affinity chromatography. J Biochem Biophys Methods 49(1–3):335–36010.1016/S0165-022X(01)00207-X ↗
11. Gaberc-Porekar V, Menart V (2005) Potential for using histidine tags in purification of proteins at large scale. Chem Eng Technol 28(11):1306–131410.1002/ceat.200500167 ↗
12. Gaberc-Porekar V, Menart V, Jevsevar S, Vidensek A, Stalc A (1999) Histidines in affinity tags and surface clusters for immobilized metal-ion affinity chromatography of trimeric tumor necrosis factor alpha. J Chromatogr A 852(1):117–12810.1016/S0021-9673(99)00374-X ↗
13. Herschke L, Lieberwirth I, Wegner G (2006a) Zinc phosphate as versatile material for potential biomedical applications Part II. J Mater Sci 17(1):95–104
14. Herschke L, Rottstegge J, Lieberwirth I, Wegner G (2006b) Zinc phosphate as versatile material for potential biomedical applications part 1. J Mater Sci 17(1):81–94
15. Hillaireau H, Couvreur P (2009) Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66(17):2873–289610.1007/s00018-009-0053-z ↗
16. Holtmann MH, Neurath MF (2004) Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 4(4):439–44410.2174/1566524043360636 ↗
17. Lee SJ, Kavanaugh A (2005) Adalimumab for the treatment of rheumatoid arthritis. Therapy 2(1):13–2110.2217/14750708.2.1.13 ↗
18. Mease JP (2009) Certolizumab pegol for rheumatoid arthritis: effective in combination with methotrexate or as monotherapy. Int J Clin Rheumatol 4(3):253–26610.2217/ijr.09.12 ↗
19. Patel JD, O’Carra R, Jones J, Woodward JG, Mumper RJ (2007) Preparation and characterization of nickel nanoparticles for binding to his-tag proteins and antigens. Pharm Res 24(2):343–35210.1007/s11095-006-9154-7 ↗
20. Spohn G, Guler R, Johansen P et al (2007) A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 178(11):7450–745710.4049/jimmunol.178.11.7450 ↗
21. Sprules T, Green N, Featherstone M, Gehring K (1998) Nickel-induced oligomerization of proteins containing 10-histidine tags. Biotechniques 25(1):20–2210.2144/98251bm02 ↗
22. Steed PM, Tansey MG, Zalevsky J, Zhukovsky EA, Desjarlais JR, Szymkowski DE, Abbott C, Carmichael D, Chan C, Cherry L et al (2003) Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301(5641):1895–189810.1126/science.1081297 ↗
23. Tabata Y, Noda Y, Matsui Y, Ikada Y (1999) Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination. J Control Release 59(2):187–19610.1016/S0168-3659(98)00190-4 ↗
24. Tian ZM, Wan MX, Wang B, Wang SP, Wu XM, Ruan YS (2003) Effects of ultrasound on the structure and function of tumor necrosis factor-alpha. Ultrasound Med Biol 29(9):1331–133910.1016/S0301-5629(03)00985-2 ↗
25. Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10(1):45–6510.1038/sj.cdd.4401189 ↗
26. Wang TW, Xu Q, Wu Y, Zeng AJ, Li MJ, Gao HX (2009) Quaternized chitosan (QCS)/poly (aspartic acid) nanoparticles as a protein drug-delivery system. Carbohydr Res 344(7):908–91410.1016/j.carres.2009.02.018 ↗
27. Watanabe M, Uchida K, Nakagaki K et al (2007) Anti-cytokine autoantibodies are ubiquitous in healthy individuals. FEBS Lett 581(10):2017–202110.1016/j.febslet.2007.04.029 ↗
28. Zuany-Amorim C, Manlius C, Dalum I et al (2004) Induction of TNF-alpha autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases. Int Arch Allergy Immunol 133(2):154–16310.1159/000076441 ↗